Catholic University of the Sacred Heart / Università Cattolica del Sacro Cuore
University / College
Location:
Mailand (Milano) / Rome (Roma),
Italy (IT)
ISNI: 0000000109413192
ROR: https://ror.org/03h7r5v07
Non-specific gastrointestinal features: Could it be Fabry disease? (2018)
Hilz MJ, Arbustini E, Dagna L, Gasbarrini A, Goizet C, Lacombe D, Liguori R, et al.
Journal article
Proposal of a rating scale to recognize Fabry disease in patients with nonspecific gastrointestinal symptoms (2018)
Hilz MJ, Arbustini E, Dagna L, Gasbarrini A, Goizet C, Lacombe D, Liguori R, et al.
Conference contribution
Do we understand the pathophysiology of gastrointestinal symptoms in patients with Fabry disease? (2018)
Hilz MJ, Arbustini E, Dagna L, Gasbarrini A, Goizet C, Lacombe D, Liguori R, et al.
Conference contribution
Pitfalls in the measurement of muscle mass: a need for a reference standard (2018)
Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, et al.
Journal article
The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al (2018)
Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, Maggi S, et al.
Journal article, Letter
The Authors reply: "Dual energy X-ray absorptiometry: gold standard for muscle mass?" by Scafoglieri et al (2018)
Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, Maggi S, et al.
Journal article, Note
The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants (2018)
Marzetti E, Cesari M, Calvani R, Msihid J, Tosato M, Rodriguez-Manas L, Lattanzio F, et al.
Journal article
Nutritional Intervention in Sarcopenia: Report from the International Conference on Frailty and Sarcopenia Research Task Force (2018)
Landi F, Sieber C, Fielding RA, Rolland Y, Guralnik J
Journal article
Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018)
Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al.
Conference contribution
Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018)
Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al.
Conference contribution